LT3200817T - Būdas ir kompozicija, skirti sustiprintų priešuždegiminių/antikatabolinių ir regeneracinių agentų gamybai iš autologinio kraujo - Google Patents

Būdas ir kompozicija, skirti sustiprintų priešuždegiminių/antikatabolinių ir regeneracinių agentų gamybai iš autologinio kraujo

Info

Publication number
LT3200817T
LT3200817T LTEPPCT/CA2015/000521T LT15847588T LT3200817T LT 3200817 T LT3200817 T LT 3200817T LT 15847588 T LT15847588 T LT 15847588T LT 3200817 T LT3200817 T LT 3200817T
Authority
LT
Lithuania
Prior art keywords
catabolic
inflammatory
composition
autologous blood
producing enhanced
Prior art date
Application number
LTEPPCT/CA2015/000521T
Other languages
English (en)
Inventor
Anthony Galea
Irina Brokhman
Original Assignee
Antnor Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antnor Limited filed Critical Antnor Limited
Publication of LT3200817T publication Critical patent/LT3200817T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
LTEPPCT/CA2015/000521T 2014-09-30 2015-09-30 Būdas ir kompozicija, skirti sustiprintų priešuždegiminių/antikatabolinių ir regeneracinių agentų gamybai iš autologinio kraujo LT3200817T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA2866480A CA2866480A1 (en) 2014-09-30 2014-09-30 Method and composition for producing enhanced anti-inflammatory and regenerative agents from autologous physiological fluid
CA2891445A CA2891445A1 (en) 2014-09-30 2015-05-14 Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid
CA2900537A CA2900537A1 (en) 2014-09-30 2015-08-13 Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid
PCT/CA2015/000521 WO2016049746A1 (en) 2014-09-30 2015-09-30 Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid

Publications (1)

Publication Number Publication Date
LT3200817T true LT3200817T (lt) 2022-08-10

Family

ID=55590205

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/CA2015/000521T LT3200817T (lt) 2014-09-30 2015-09-30 Būdas ir kompozicija, skirti sustiprintų priešuždegiminių/antikatabolinių ir regeneracinių agentų gamybai iš autologinio kraujo

Country Status (16)

Country Link
US (2) US10532072B2 (lt)
EP (1) EP3200817B1 (lt)
JP (1) JP6646660B2 (lt)
KR (1) KR102455394B1 (lt)
CN (1) CN107073083B (lt)
AU (1) AU2015327723B2 (lt)
BR (1) BR112017006410A2 (lt)
CA (4) CA2866480A1 (lt)
CL (1) CL2017000670A1 (lt)
ES (1) ES2912773T3 (lt)
GB (1) GB2546224B (lt)
IL (1) IL251082B (lt)
LT (1) LT3200817T (lt)
MX (1) MX2017004131A (lt)
RU (1) RU2708242C2 (lt)
WO (1) WO2016049746A1 (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2866480A1 (en) 2014-09-30 2016-03-30 Antnor Limited Method and composition for producing enhanced anti-inflammatory and regenerative agents from autologous physiological fluid
CA2950659A1 (en) * 2016-12-06 2018-06-06 Antnor Limited Method for the preparation and prolonged storage of growth factors and cytokines obtained from platelet rich plasma
EP3613424A1 (en) * 2018-08-23 2020-02-26 Orthogen AG Novel methods for the production of pharmaceutical agents
WO2020243807A1 (en) * 2019-06-05 2020-12-10 Antnor Limited Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid
RU2747589C1 (ru) * 2019-12-09 2021-05-11 Руслан Яверович Атлуханов Способ лечения повреждения мениска коленного сустава
CA3076046A1 (en) * 2020-03-17 2021-09-17 Antnor Limited Method for producing enhanced anti-inflammatory/anti-catabolic agents from autologous physiological fluid with shortened incubation time
CA3106197A1 (en) * 2021-01-20 2022-07-20 Antnor Limited Method for producing blood plasma product useful in the treatment of viral infections characterized by an uncontrolled release of proinflammatory cytokines
JP7025070B1 (ja) * 2021-05-14 2022-02-24 セルソース株式会社 血液由来成長因子含有組成物及びその調製方法
JP7175055B1 (ja) * 2021-05-14 2022-11-18 セルソース株式会社 血液由来成長因子含有組成物及びその調製方法
CN114146096B (zh) * 2021-11-25 2024-04-02 成都清科生物科技有限公司 一种富含细胞因子的条件血清的制备方法及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018292A1 (en) 1994-12-16 1996-06-20 Baxter International Inc. Controlling donor blood characteristics
DE19903876B4 (de) * 1999-02-01 2006-09-28 Orthogen Gentechnologie Gmbh Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten
US20060177515A1 (en) 2005-02-09 2006-08-10 Reinhold Schmieding Method of producing autogenous or allogenic blood serum and related logistics
GB0700940D0 (en) 2007-01-18 2007-02-28 Univ Newcastle Reverse shoulder prosthesis
EP2567692B1 (en) 2008-02-27 2016-04-06 Biomet Biologics, LLC Use of a device for obtaining interleukin-1 receptor antagonist rich solutions
US8460227B2 (en) * 2008-11-17 2013-06-11 Arthrex, Inc. Cytokine concentration system
AU2010292486B2 (en) 2009-08-27 2014-08-07 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
AU2011296356B2 (en) 2010-09-03 2015-07-09 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
KR101313755B1 (ko) * 2010-12-09 2013-10-01 이선민 상피조직 또는 피하조직 재생용 자가혈장의 제조방법 및 이를 함유하는 조성물
WO2013114359A1 (en) 2012-01-31 2013-08-08 Estar Technologies Ltd System and method for producing interleukin receptor antagonist (ira)
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
CA2866480A1 (en) 2014-09-30 2016-03-30 Antnor Limited Method and composition for producing enhanced anti-inflammatory and regenerative agents from autologous physiological fluid

Also Published As

Publication number Publication date
KR20170063836A (ko) 2017-06-08
WO2016049746A1 (en) 2016-04-07
RU2708242C2 (ru) 2019-12-05
CA2866480A1 (en) 2016-03-30
KR102455394B1 (ko) 2022-10-17
CA2962289C (en) 2021-01-19
US20200163991A1 (en) 2020-05-28
AU2015327723B2 (en) 2020-10-22
CN107073083B (zh) 2021-07-06
ES2912773T3 (es) 2022-05-27
AU2015327723A1 (en) 2017-04-13
CL2017000670A1 (es) 2017-11-10
RU2017114523A (ru) 2018-11-07
CA2962289A1 (en) 2016-04-07
MX2017004131A (es) 2017-06-19
EP3200817B1 (en) 2022-03-02
JP2017533896A (ja) 2017-11-16
GB2546224A (en) 2017-07-12
CA2900537A1 (en) 2016-03-30
CA2891445A1 (en) 2016-03-30
US20170296583A1 (en) 2017-10-19
JP6646660B2 (ja) 2020-02-14
EP3200817A4 (en) 2018-06-20
CN107073083A (zh) 2017-08-18
US10532072B2 (en) 2020-01-14
IL251082A0 (en) 2017-04-30
RU2017114523A3 (lt) 2019-05-06
GB2546224B (en) 2020-04-22
IL251082B (en) 2020-03-31
BR112017006410A2 (pt) 2017-12-19
EP3200817A1 (en) 2017-08-09
GB201706803D0 (en) 2017-06-14

Similar Documents

Publication Publication Date Title
IL251082A0 (en) Method and composition for the production of improved anti-inflammatory/anti-catabolism and regenerative substances from patient-derived physiological fluids
HK1245661A1 (zh) 納米顆粒組合物和用於免疫療法的方法
IL250744A0 (en) A method for preparing flavociclib and its pharmaceutical preparations
IL279627A (en) A method for treating depression
IL246791A0 (en) Compositions and methods for treating eye diseases
ZA201707303B (en) Compositions and methods for the treatment of immunodeficiency
EP3099296A4 (en) Isoindoline compositions and methods for treating neurodegenerative disease
EP3102233A4 (en) Methods and compositions for treating cancer and infectious diseases
EP3199169A4 (en) Composition containing mesenchymal stem cell-hydrogel and method for producing the composition
EP3139928A4 (en) Anordrin compositions and methods for treating diseases
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
EP3110446A4 (en) Methods and compositions for treating siglec-8 associated diseases
PL3139770T3 (pl) Kompozycja kwasów tłuszczowych, sposób jej wytwarzania i jej zastosowanie
HK1246193A1 (zh) 用於改善認知的方法和組合物
HK1245127A1 (zh) 治療腦疾病的方法和組合物
EP3132795A4 (en) Composition for preventing or treating fatty liver diseases
ZA201606199B (en) Compositions and methods for treating diabetes and liver diseases
EP3137907A4 (en) Methods and compositions for the diagnosis and treatment of kawasaki disease
EP3214172A4 (en) Method for producing remcombinant human dnasei
EP3238703A4 (en) Method for producing liquid composition for oral cavity and liquid composition for oral cavity
EP3159379A4 (en) Siloxane composition and method for producing same
IL248779A0 (en) Pharmaceutical preparations for the treatment of infectious diseases
EP3164132A4 (en) Methods and compositions for treating diseases and conditions
IL248210A0 (en) Methods and preparations for the treatment of blood vessel malformations
GB201612282D0 (en) Process and composition for producing oil